Deep sequencing of HIV: Clinical and research applications

Annual Review of Genomics and Human Genetics

Volumn 15, Issue , 2014, Pages 295-325

  Chabria, Shiven B ^a   Gupta, Shaili ^a,b   Kozal, Michael J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

deep sequencing; HIV quasispecies; low frequency variants; mutant variants; transmitted drug resistance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; GENE MUTATION; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; NONHUMAN; PREVALENCE; REVIEW; TREATMENT RESPONSE; TROPISM; VIRAL GENETICS; VIROLOGY; VIRUS MORPHOLOGY; VIRUS REPLICATION; CHEMISTRY; GENETICS; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; MUTATION; PATHOGENICITY; TRANSMISSION; VIRUS GENOME;

DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV; HIV INFECTIONS; HUMANS; MUTATION;

EID: 84906859400     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-091212-153406     Document Type: Review

References (162)

1. Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, et al. 2012. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naive behaviorally HIV-infected youth. AIDS Patient Care STDs 26:193-96
2. Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, et al. 2003. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J. Clin. Virol. 26:153-61
3. An M, Han X, Xu J, Chu Z, Jia M, et al. 2012. Reconstituting the epidemic history of HIV strain CRF01-AE among men who have sex with men (MSM) in Liaoning, northeastern China: implications for the expanding epidemic among MSM in China. J. Virol. 86:12402-6
4. Antiretrovir. Ther. Cohort Collab. 2008. Life expectancy of individuals on combination antiretrovi-ral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293-99
5. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, et al. 2012. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by Ultra-Deep 454 Pyrosequencing. J. Infect. Dis. 205:557-67
6. Balazs AB, West AP. 2013. Antibody gene transfer for HIV immunoprophylaxis. Nat. Immunol. 14:1-5
7. Bañez Ocfemia MC, Saduvala N, Oster AM, Kim D, Kline R, et al. 2014. Transmitted HIV-1 drug resistance among men who have sex with men, 11 US jurisdictions, 2008-2011. In CROI 2014: Conference on Retroviruses and Opportunistic Infections, March 3-6, Boston, Abstr. 579. San Francisco: IAS-USA/CROI
8. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15:1181-83
9. Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, et al. 2006. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J. Infect. Dis. 194:1309-18
10. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-68
11. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, et al. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-5
12. Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, et al. 2011. Detection of inferred CCR5-and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog. 7:e1002106
13. Castor D, Low A, Evering T, Karmon S, Davis B, et al. 2012. Transmitted drug resistance and phylo-genetic relationships among acute and early HIV-1-infected individuals in New York City. J. Acquir. Immune Defic. Syndr. 61:1-8
14. Cent. Dis. Control Prev. 2012. Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2011. HIV Surveill. Rep. Vol. 23, Cent. Dis. Control Prev., Atlanta, GA. http://www.cdc.gov/hiv/library/reports/ surveillance/2011/surveillance-Report-vol-23.html
15. Chibo D, Kaye M, Birch C. 2012. HIV transmissions during seroconversion contribute significantly to new infections in men who have sex with men in Australia. AIDS Res. Hum. Retrovir. 28:460-64
16. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-88
17. Cladera J, Martin I, O'Shea P. 2001. The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface. EMBO J. 20:19-26
18. Codoñer FM, Pou C, Thielen A, García F, Delgado R, et al. 2010. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antivir. Res. 88:281-86
19. Codoñer FM, Pou C, Thielen A, García F, Delgado R, et al. 2011. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS ONE 6:e19461
20. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-89
21. Collins FS, Hamburg MA. 2013. First FDA authorization for next-generation sequencer. N. Engl. J. Med. 369:2369-71
22. Cong ME, Heneine W, Garcia-Lerma JG. 2007. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulatedby mutational interactions. J. Virol. 81:3037-41
23. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. 2010. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24:2263-70
24. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-67
25. de Sa-Filho DJ, Ambar RF, Duarte NB, Matias RB, Candido V, et al. 2009. HIV type 1 diversity from newly diagnosed patients in Santos metropolitan area/Brazil. AIDS Res. Hum. Retrovir. 25:925-29
26. Dep. Health Hum. Serv. Panel Antiretrovir. Guidel. Adults Adolesc. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rep., Dep. Health Hum. Serv., Washington, DC. http://aidsinfo.nih. gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
27. Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, et al. 2008. Viral population estimation using pyrosequencing. PLoS Comput. Biol. 4:e1000074
28. Escoto-Delgadillo M, Vázquez-Valls E, Ramírez- Rodríguez M, Corona-Nakamura A, Amaya-Tapia G, et al. 2005. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med. 6:403-9
29. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, et al. 2012. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J. Virol. 86:6231-37
30. Frentz D, Boucher CA, van de Vijver DA. 2012. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 14:17-27
31. Fujisaki S, Ibe S, Hattori J, Shigemi U, Fujisaki S, et al. 2009. An 11-year surveillance of HIV type 1 subtypes in Nagoya, Japan. AIDS Res. Hum. Retrovir. 25:15-21
32. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-41
33. Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, et al. 2007. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antivir. Res. 75:75-82
34. Gega A, Kozal MJ. 2010. New technology to detect low-level drug-resistant HIV variants. Future Virol. 6:17-26
35. Gianella S, Richman DD. 2010. Minority variants of drug-resistant HIV. J. Infect. Dis. 202:657-66
36. Gill B, Okie S. 2007. China and HIV-a window of opportunity. N. Engl. J. Med. 356:1801-5
37. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, et al. 2012. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380:1250-58
38. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, et al. 2010. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J. Infect. Dis. 201:672-80
39. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, et al. 2012. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect. Dis. 12:307-17
40. Harrigan PR, Geretti AM. 2011. Genotypic tropism testing: evidence-based or leap of faith? AIDS 25:257-64
41. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, et al. 2010. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antivir. Res. 88:72-79
42. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, Kunz A. 2011. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS ONE 6:e20357
43. Hawke KG, Waddell RG, Gordon DL, Ratcliff RM, Ward PR, Kaldor JM. 2013. HIV non-B subtype distribution: emerging trends and risk factors for imported and local infections newly diagnosed in South Australia. AIDS Res. Hum. Retrovir. 29:311-17
44. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, et al. 2012. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 8:e1002529
45. Ho DD. 1997. Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J. Clin. Investig. 99:2565-67
46. Hogg RS, Althoff KN, Samji H, Cescon A, Modur S, et al. 2013. Increases in life expectancy among treated HIV-positive individuals in the United States and Canada, 2000-2007. Presented at Int. AIDS Soc. Conf. HIV Pathog. Treat. Prev., 7th, Kuala Lumpur, Malays., June 30-July 3. Abstr. TUPE260. http://pag.ias2013.org/Abstracts.aspx?AID =2451
47. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, et al. 2002. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16:1051-58
48. Homs M, Buti M, Quer J, Jardí R, Schaper M, et al. 2011. Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motifofthe viral polymeraseinthe same viral genome. Nucleic Acids Res. 39:8457-71
49. Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR. 2011. The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. Infect. Disord. Drug Targets 11:124-33
50. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. 2011. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 108:20166-71
51. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. 2010. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5:e15510
52. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, et al. 2006. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J. Acquir. Immune Defic. Syndr. 42:86-90
53. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158
54. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. 2013. Update of the drug resistance mutations in HIV-1: March 2013. Top. Antivir. Med. 21:6-14
55. Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, et al. 2012. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS ONE 7:e46334
56. Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, et al. 2001. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir. Ther. 6:71-77
57. Kim D, Ziebell R, Saduvala N, Kline R, Bañez Ocfemia C, et al. 2013. Trend in transmitted HIV-1 ARV drug resistance-associated mutations: 10 HIV surveillance areas, US, 2007-2010. Presented at Conf. Retrovir. Oppor. Infect., 20th, Atlanta, GA, March 3-6
58. Korn K, Reil H, Walter H, Schmidt B. 2003. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J. Clin. Microbiol. 41:3559-65
59. Kozal MJ. 2009. Drug resistant HIV. Clin. Microbiol. Infect. 15(Suppl. 1):69-73
60. Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, et al. 2011. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels. Antivir. Ther. 16:925-29
61. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al. 2012. A nucleoside-and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin. Trials 13:119-30
62. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-32
63. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-25
64. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS. 2008. Profile of primary resistance in HIV-1-infected treatment-naive individuals from western India. AIDS Res. Hum. Retrovir. 24:987-90
65. Larder BA, Darby G, Richman DD. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-34
66. Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, et al. 2012. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS ONE 7:e30118
67. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, et al. 2010. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE 5:e10952
68. Lauck M, Alvarado-Mora MV, Becker EA, Bhattacharya D, Striker R, et al. 2012. Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. J. Virol. 86:3952-60
69. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. 2009. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 4:e6079
70. Lee GQ, Harrigan PR, Dong W, Poon AF, Heera J, et al. 2013. Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original Trofile assay in non-B subtypes. AIDS Res. Hum. Retrovir. 29:979-84
71. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. 2007. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr. HIV Res. 5:97-107
72. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, et al. 2011. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J. Infect. Dis. 203:798-802
73. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, et al. 2013. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutationson resistance genotype after virologic failure. J. Infect. Dis. 207:893-97
74. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. 2011. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305:1327-35
75. Liao L, Xing H, Li X, Ruan Y, Zhang Y, et al. 2007. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res. Hum. Retrovir. 23:1062-65
76. Lin NH, Kuritzkes DR. 2009. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 4:481-87
77. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, et al. 2008. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol. 82:5510-18
78. Littman DR. 1998. Chemokine receptors: keys to AIDS pathogenesis? Cell 93:677-80
79. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, et al. 2011. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob. Agents Chemother. 55:1114-19
80. Lucas GM, Chaisson RE, Moore RD. 1999. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131:81-87
81. Luciani F, Bull RA, Lloyd AR. 2012. Next generation deep sequencing and vaccine design: today and tomorrow. Trends Biotechnol. 30:443-52
82. Macalalad AR, Zody MC, Charlebois P, Lennon NJ, Newman RM, et al. 2012. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput. Biol. 8:e1002417
83. Machado LY, Dubed M, Díaz H, Ruiz N, Romay D, et al. 2013. Transmitted HIV type 1 drug resistance in newly diagnosed Cuban patients. AIDS Res. Hum. Retrovir. 29:411-14
84. Marcellin F, Boyer S, Protopopescu C, Dia A, Ongolo-Zogo P, et al. 2008. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116). Trop. Med. Int. Health 13:1470-78
85. Mardis ER. 2008. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 9:387-402
86. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, et al. 2009. Ultra-deep pyrose-quencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 199:1275-85
87. Markovitz AR, Thibault CS, Brandauer PW, Buskin SE. 2011. Primary antiretroviral drug resistance in newly human immunodeficiency virus-diagnosed individuals testing anonymously and confidentially. Microb. Drug Resist. 17:283-89
88. Menéndez-Arias L. 2002. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23:381-88
89. Metzker ML. 2010. Sequencing technologies-the next generation. Nat. Rev. Genet. 11:31-46
90. Mich. Dep. Community Health. 2013. HIV genotype surveillance in Michigan 2004-2012. Rep., Mich. Dep. Community Health, Lansing, MI. http://www.michigan. gov/documents/mdch/VARHS-report- final-427665-7.pdf
91. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, et al. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-67
92. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. 2006. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296:679-90
93. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, et al. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82:8422-30
94. Moore JP. 1997. Coreceptors: implications for HIV pathogenesis and therapy. Science 276:51-52
95. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. 2007. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann. Intern. Med. 146:564-73
96. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, et al. 2004. Adherence to antiretro-viral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res. Hum. Retrovir. 20:1053-56
97. Nicot F, Saliou A, Raymond S, Saune K, Dubois M, et al. 2012. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J. Clin. Virol. 55:107-13
98. Palacios R, Viciana I, Pérez de Pedro I, de la Torre J, Ropero F, et al. 2008. Prevalencia de mutaciones de resistencia primaria en los nuevos diagnósticos de infección por el VIH en la provincia de Málaga [Prevalence of primary resistance mutations in patients with newly diagnosed HIV infection in the province of Málaga (Spain)]. Enferm. Infecc. Microbiol. Clín. 26:141-45
99. Parreira R, Piedade J, Domingues A, Lobão D, Santos M, et al. 2006. Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique. Microbes Infect. 8:2442-51
100. Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, et al. 1997. Geographical distribution of HIV-1 group O viruses in Africa. AIDS 11:493-98
101. Piot P, Quinn TC. 2013. Response to the AIDS pandemic-a global health model. N. Engl. J. Med. 368:2210-18
102. Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, et al. 2011. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS ONE 6:e21189
103. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, et al. 2011. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J. Antimicrob. Chemother. 66:1886-96
104. Ragonnet-Cronin M, Ofner-Agostini M, Merks H, Pilon R, Rekart M, et al. 2010. Longitudinal phy-logenetic surveillance identifies distinct patterns of cluster dynamics. J. Acquir. Immune Defic. Syndr. 55:102-8
105. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. Am. 42:401-7
106. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, et al. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J. Acquir. Immune Defic. Syndr. 59:39-46
107. Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, et al. 2012. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS ONE 7:e37874
108. Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, et al. 2010. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res. Hum. Retrovir. 26:293-300
109. Saad MD, Aliev Q, Botros BA, Carr JK, Gomatos PJ, et al. 2006. Genetic forms of HIV type 1 in the former Soviet Union dominate the epidemic in Azerbaijan. AIDS Res. Hum. Retrovir. 22:796-800
110. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-67
111. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, et al. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713
112. Schadt EE, Turner S, Kasarskis A. 2010. A window into third-generation sequencing. Hum. Mol. Genet. 19:R227-40
113. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 194(Suppl. 1):S51-58
114. Shafer RW. 2009. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J. Infect. Dis. 199:610-12
115. Sigaloff KC, Mandaliya K, Hamers RL, Otieno F, Jao IM, et al. 2012. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res. Hum. Retrovir. 28:1033-37
116. Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, et al. 2010. A multicenter collaborative study on HIV drug resistance testing using 454 massively parallel pyrosequencing. Antivir. Ther. 15(Suppl. 2):A37
117. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701
118. Simons JF, Egholm M, Lanza J, Truenchalk G, Desany B, et al. 2005. Ultra-deep sequencing of HIV clinical samples. Antivir. Ther. 10(Suppl. 1):A157
119. Sinha S, Ahmad H, Shekhar RC, Kumar N, Dar L, et al. 2012. Prevalence of HIV drug resistance mutations in HIV type 1 isolates in antiretroviral therapy naive population from northern India. AIDS Res. Treat. 2012:905823
120. Skums P, Dimitrova Z, Campo DS, Vaughan G, Rossi L, et al. 2012. Efficient error correction for next-generation sequencing of viral amplicons. BMC Bioinforma. 13(Suppl. 10):S6
121. Stanford Univ. 2013. HIV drug resistance database: mutation list analysis. Version 6.3.1, updated Sept. 20, accessed Dec. 13. http://sierra2.stanford.edu/sierra/servlet/JSierra?action = mutationsInput
122. Stanford Univ. 2013. HIV-1 drug resistance in ARV-naive populations. Accessed Dec. 13. http://hivdb. stanford.edu/surveillance/map
123. Stenman J, Lintula S, Rissanen O, Finne P, Hedstrom J, et al. 2003. Quantitative detection of low-copy-number mRNAs differing at single nucleotide positions. BioTechniques 34:172-77
124. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, et al. 2003. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 100:4819-24
125. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. 2008. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J. Clin. Virol. 41:310-13
126. Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H. 2012. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J. Clin. Microbiol. 50:3267-74
127. Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, et al. 2013. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob. Agents Chemother. 57:6122-30
128. Swenson LC, Däumer M, Paredes R. 2012. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 7:478-85
129. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237-45
130. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. 2011. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis. 53:732-42
131. Tang MW, Liu TF, Shafer RW. 2012. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 55:98-101
132. Thielen A, Lengauer T. 2012. Geno2pheno[454]: a web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data. Intervirology 55:113-17
133. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. 2009. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 4:e5683
134. Tu YQ, Wang MJ, Yao J, Zhu XM, Pan PL, et al. 2009. Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in Yunnan, China. Transfusion 49:1865-73
135. UNAIDS. 2013. Global report: UNAIDS report on the global AIDS epidemic 2013. Rep. JC2502/1/E, UNAIDS, Geneva, Switz. http://www.unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report- 2013-en.pdf
136. Valle-Bahena OM, Ramos-Jiménez J, Ortiz-López R, Revol A, Lugo-Trampe A, et al. 2006. Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients. Arch. Med. Res. 37:1022-27
137. van de Vijver DA, Wensing AM, Asjo B, Bruckova M, Jorgensen LB, et al. 2010. HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. Acta Dermatoven-erol. Alp. Panon. Adriat. 19:3-9
138. Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, et al. 2007. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J. Clin. Virol. 39:43-47
139. Van Tam V, Pharris A, Thorson A, Alfven T, Larsson M. 2011. "It is not that I forget, it's just that I don't want other people to know": barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care 23:139-45
140. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, et al. 2009. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 52:309-15
141. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, et al. 2010. Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation. PLoS ONE 5:e10992
142. Vaughan HE, Cane P, Pillay D, Tedder RS. 2003. Characterization of HIV type 1cladesinthe Caribbean using pol gene sequences. AIDS Res. Hum. Retrovir. 19:929-32
143. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-46
144. Wainberg MA. 2012. The need for development of new HIV-1 reverse transcriptase and integrase inhibitors in the aftermath of antiviral drug resistance. Scientifica 2012:238278
145. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17:1195-201
146. + T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. J. Virol. 83:1845-55
147. Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, et al. 2013. Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. J. Clin. Microbiol. 51:1517-27
148. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, et al. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189:2174-80
149. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, et al. 2009. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J. Acquir. Immune Defic. Syndr. 52:574-80
150. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192:958-66
151. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. 2010. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24:1203-12
152. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, et al. 2002. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 16:F41-47
153. WHO (World Health Organ.). 2012. WHO HIV drug resistance report 2012. Rep., WHO, Geneva, Switz.
154. http://www.who.int/hiv/pub/drugresistance/report2012
155. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. 2011. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect. Dis. 11:363-71
156. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-602
157. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-88
158. Yang R, Xia X, Kusagawa S, Zhang C, Ben K, Takebe Y. 2002. On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China. AIDS 16:1401-7
159. Yanik EL, Napravnik S, Hurt CB, Dennis A, Quinlivan EB, et al. 2012. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J. Acquir. Immune Defic. Syndr. 61:258-62
160. Zagordi O, Klein R, Däumer M, Beerenwinkel N. 2010. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 38:7400-9
161. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, et al. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245-58
162. Zhu J, Wu X, Zhang B, McKee K, O'Dell S, et al. 2013. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc. Natl. Acad. Sci. USA 110:E4088-97